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Chemotherapy for patients with multiple parasitic
infections
P. L. CHIODINI*
Department of Clinical Parasitology, The Hospital for Tropical Diseases, London WC1E 6AU
summary
Multiple parasitic infections have become increasingly recognized as a result of improvements in laboratory diagnosis and
a growing population of immunocompromised individuals. This review examines the principles of chemotherapy in
groupings of multiple infections which are of particular clinical significance.
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introduction
Conventional medical training teaches medical
students to make a single unifying diagnosis when
analysing a clinical problem. Parasitology is an
important exception to this rule and, especially in the
tropics, it is common for an individual patient to
harbour more than one parasite, sometimes in
different organ systems or, especially in the case of
the gastrointestinal tract, in the same one (Kang et
al. 1998).
The approach to chemotherapy of multiple para-
sitic infections depends upon the following prin-
ciples. (1) Precise diagnosis. At times this can be
surprisingly difficult – in tropical areas diagnostic
laboratory provision can vary from nil to soph-
isticated, but is most denied to those most affected
by parasitic disease. This has led to syndromic
treatment protocols and empirical, often broad-
spectrum, antiparasitic therapy. In aﬄuent countries
with well equipped laboratory services, lack of
experience can still lead to difficulties in confirming
the diagnosis outside reference centres, though
external quality assessment schemes, e.g.
UKNEQAS, have raised standards in recent years
(Kettelhut et al. 1994). (2) The choice of narrow
versus broad-spectrum agents is influenced by access
to accurate laboratory diagnosis and by cost (both of
diagnostic tests and the drugs required). (3) Whether
an individual or the community is being treated. (4)
The possibility of drug interaction if two or more
antiparasitic agents are given simultaneously for
multiple parasitic infections. (5) Where chemo-
therapy for one parasite might produce compli-
cations due to its action on another parasite present
simultaneously. (6) In an individual case, which
parasite predominates as the cause of disease.
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Multiple parasitic infections can occur in many
potential combinations but there are certain
groupings which are of particular significance and
are considered below.
onchocerciasis and loiasis
When ivermectin was under consideration as part of
the Onchocerciasis Control Programme (OCP), its
safety in community-based mass treatment pro-
grammes in geographical areas where the population
harbours multiple filarial infections plus intestinal
nematodes, was clearly critical to the acceptability
and potential success of the mass treatment pro-
gramme.
Richard-Lenoble et al. (1988) examined the safety
and efficacy of ivermectin in patients with multiple
filarial infections in Gabon. Seventeen patients with
concomitant Loa loa and Onchocerca volvulus were
studied. Other nematode infections found in this
group were Mansonella perstans (five patients) and
intestinal nematodes (16 patients). Each patient
received ivermectin 200 lg}kg as a single dose. Ten
days later, the mean Loa loa microfilarial count had
fallen to twenty per cent of the mean level before
treatment, and Onchocerca volvulus dermal micro-
filarial densities were only 2% of the pre-treatment
values, whilst Mansonella perstans microfilarial
counts were unaffected by ivermectin. By day 23,
15}15 with Ascaris infection had been parasito-
logically cured, but there had been no significant
effect upon infections with Trichuris trichiura or
Necator americanus. Ten (59%) patients suffered
pruritis one to five days post treatment, though
neither antihistamines nor corticosteroids were
required for symptomatic relief. However, the mean
Loa loa microfilarial count was less than 300}ml of
blood, so the tolerance of ivermectin with high
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microfilarial counts could not be determined by this
study.
In 1995, the African Programme for Oncho-
cerciasis Control (APOC) was launched, to develop
community-based ivermectin treatment programmes
in the nineteen Onchocerca volvulus endemic African
countries outside the Onchocerca Control Pro-
gramme in West Africa. Of the 19 participating
countries, 12 have foci of Loa loa infection. Gardon
et al. (1997) studied the incidence of serious adverse
events following country-based ivermectin treatment
in a part of Cameroon where onchocerciasis and
loaisis were both endemic and explored the re-
lationship between serious adverse events and pre-
treatment Loa loa microfilarial counts. Of 17877
patients treated, 20 developed serious non-neuro-
logical reactions, one of them fatal. Two patients
developed serious neurological reactions, including
coma, from which they had recovered after a month.
Both had pre-treatment microfilarial counts in excess
of 50000}ml. It was possible to record the pre-
treatment microfilarial count for 5500 patients and
the initial Loa loa microfilarial load was the main risk
factor for the development of serious reactions; the
risk increasing with microfilarial intensity. The
association between microfilarial load and the oc-
currence of marked or serious reactions was
significant above 8000 microfilaria}ml of blood. The
occurrence of serious reactions was closely related to
the Loa loa microfilarial load (odds ratio 114–7). The
authors noted three previous cases of Loa loa
encephalopathy related to ivermectin, also from
Cameroon, and estimated the incidence of serious
neurological reactions to be approximately 1–1 per
10000 people. The authors concluded that in areas
where loiasis and onchocerciasis co-exist, the use of
ivermectin should be carefully considered if the
onchocerciasis does not present a serious public
health problem locally. In other areas, where oncho-
cerciasis is blinding or severely disabling, persons at
risk need to be identified. Ivermectin appears able to
provoke the passage of microfilariae of Loa loa into
the cerebrospinal fluid (CSF) (Ducorps et al. 1995).
A probable case of Loa loa encephalopathy related to
ivermectin (PLERI) has been defined by four
criteria : occurrence of a coma in a person who was
previously healthy and has no other cause for the
coma; onset of CNS symptoms and signs within 5
days of ivermectin therapy and progression to coma
without remission; Loa loa microfilaraemia of greater
than or equal to 10 000 microfilariae}ml pre-treat-
ment or greater than or equal to 1000 microfilariae
per ml within two months after treatment; the
presence of Loa loa microfilariae in the CSF.
Boussinesq et al. (1998) gave detailed descriptions
of the PLERI cases noted by Gardon et al. (1997)
which occurred in an area of Cameroon where
40–95% of the population had dermal microfilariae
of Onchocerca and 10–33% had Loa loa micro-
filaraemia. Of 17 877 persons treated with ivermectin
150 lg}kg, two developed encephalopathy and
twenty developed milder neurological reactions, with
functional impairment requiring assistance to per-
form everyday domestic activities, but without
disorders of consciousness or neurological signs.
Boussinesq et al. (1998) reviewed a total of five
PLERI cases. All occurred in young, previously
healthy males. Initial symptoms, including fatigue,
headache and joint pains, appeared on day one or
two post-ivermectin. Disordered consciousness was
usually manifest on day three or four. The patients
were usually incontinent for several days, but the
motor deficit was usually mild. Tendon reflexes were
absent in three and brisk in one case; cog-wheeling
was seen in two patients. All three individuals whose
fundi were examined had retinal haemorrhages. Two
patients died, one from gastrointestinal haemorrhage
and one as a result of secondary bacterial infection.
In both cases the diagnosis of PLERI was made too
late for them to receive adequate therapy. In the
three survivors, the clinical picture was most severe
on days four or five, then showed progressive
improvement, with almost full recovery one month
after ivermectin therapy. Peripheral blood micro-
filarial counts were very high in all five PLERI cases
and all had microfilariae in the CSF.
The major risk factor for PLERI is the peripheral
blood microfilarial count (a level above 30000
microfilariae}ml has been quoted as the risk
threshold, (Chippaux et al. 1996) though a variety of
co-factors has been suggested.
Treatment of PLERI involves good supportive
care in hospital, antihistamines and}or cortico-
steroids, and early detection and treatment of
secondary infection (Boussinesq et al. 1998). Pre-
vention of PLERI depends upon identification of
individuals at risk from a high microfilarial load; a
difficult task without taking pre-treatment blood
samples from the population in areas with a
significant overlap of Onchocerca volvulus and Loa
loa infections.
intestinal helminths
In cases of mixed intestinal helminthic infections,
the effect on the human host is influenced by the
relative intensity of the infections present. For
example, Sakti et al. (1999) studied cognitive
functioning in a population of Indonesian school
children in whom there was a 43% prevalence of
helminth infection (24% hookworm; 24% Trichuris
trichiura ; 8% Ascaris lumbricoides). Lower cognitive
test scores were most apparent in children infected
with hookworm rather than other helminths. The
authors suggested this may be because the prevalence
and}or intensity of infection with Ascaris or Trichuris
were sufficiently low so as not to be responsible for
significant morbidity or a public health problem.
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This contrasts with other studies where Trichuris
infection has exerted a significant influence on
cognitive test scores.
As hookworm, Ascaris and Trichuris all respond to
single dose (400 mg) albendazole therapy (Johnson
& Soave, 1999), in cases of mixed infection there is
no clinical need to determine which of them is acting
as the predominant pathogen either in an individual
or community treatment setting. However, uptake of
therapy is a major determinant of treatment success
or failure, with a tendency for polypharmacy to
result in reduced compliance. Thus, where the
pattern of mixed infection dictates the use of two or
more different drugs, e.g. praziquantel for schisto-
somiasis and albendazole for hookworm, a common
delivery system should be deployed (Lwambo et al.
1999).
Intestinal nematodes and protozoa often coincide
in infections of the gastrointestinal tract and
Penggabean et al. (1998) examined the efficacy of
albendazole on Trichuris and Giardia infections in
rural Malaysia. Albendazole 400 mg daily for three
days was followed by cure rates of 91–5% for T.
trichiura and 96–6% for G. intestinalis. Reynoldson et
al. (1998) studied the effect of albendazole, 400 mg
daily for 5 days, on giardiasis and hookworm
infection in an Aboriginal community in Western
Australia. The prevalence of Giardia fell from 36–6%
pre-treatment to 12% between days 6 and 9, 15%
for days 10 to 17 and rose to 28% between days 18
and 30. Hookworm prevalence fell from 76% pre-
albendazole to 2% between days 6–9 and was zero by
days 18–30.
Community anthelminthic therapy is reviewed in
detail in the chapter by Drake and Bundy in this
supplement to which the reader is referred. There is
still much work to do in studying the effects of
treating geohelminth infection (multiple or single) in
children and there will be no shortage of debate. For
example, a recent Cochrane review concluded that
public health investments in routine treatment of
children in areas where helminths are common,
based on the expectation of improved growth and
learning, are not based on consistent or reliable
evidence (Dickson et al. 2000).
schistosomiasis
Recognition that co-infection with schistosomes and
intestinal helminths was common in various parts of
Africa (Adewunmi et al. 1993; Birrie, Erko & Tedla
1994) has been followed by studies to assess the
safety and efficacy of simultaneous combined mass
treatment programmes.
Nokes et al. (1999) studied the effects of combined
albendazole (400 mg single dose) and praziquantel
(60 mg}kg split dose 3 h apart) for the treatment of
geohelminth infections and Schistosoma japonicum
infections respectively. Neither drug affected the
cure rate of the other drug and co-administration of
these agents was both safe and effective. Beasley et
al. (1999) demonstrated haematological benefits
(reduced fall in haemoglobin) from single dose
albendazole (400 mg) and praziquantel (40 mg}kg)
treatment compared to placebo in almost half of
school children co-infected with geohelminths and
Schistosoma haematobium in Tanga, Tanzania.
Schistosomiasis has also been associated with
relapses of enteric fever (Gendrel et al. 1994),
and persistent Salmonella bacteraemia in AIDS
(Lambertucci, Rayes & Gerspacher-Lara 1998);
persistent Salmonella bacteraemia appears to ex-
acerbate a pre-existing sub-clinical schistosomal
glomerulopathy (Martinelli et al. 1992). Acute
schistosomiasis has been reported to facilitate the
development of Staphylococcus aureus liver abscesses
(Lambertucci et al. 1998). Detailed discussion of
these issues is outside the remit of this review, but
effective treatment for schistosomiasis is required in
each case.
malaria
Most infections with the human malaria parasites
Plasmodium falciparum, P. vivax, P. ovale and P.
malariae occur as single species. In cases where a
patient harbours more than one species of malaria
parasite, one or other species tends to be more
numerous in the blood film, such that identification
of the second species by microscopy can be very
difficult, especially when young ring stages pre-
dominate in the blood film under examination. The
advent of molecular techniques for the detection of
malaria parasites has led to greater appreciation of
the importance of mixed malarial infections. Brown
et al. (1992) conducted a prospective comparison of
microscopic diagnosis and PCR for the circum-
sporozoite gene for Plasmodium falciparum and for P.
vivax in Thai soldiers. Of 137 consecutive cases of
malaria, 3}32 (9%) of microscopically diagnosed P.
falciparum infections and 5}104 (5%) of micro-
scopically diagnosed P. vivax infections were found
to be mixed by PCR. One case was diagnosed as
mixed by microscopy and PCR. Pieroni et al. (1998)
reported on 148 travellers with malaria as determined
by PCR and microscopy, six (4–1%) of whom were
shown to have mixed infections.
Treatment of mixed malarial infections is species
dependent. In all cases the first priority is to treat the
asexual erythrocytic stages as they are responsible
for the malarial illness. If P. falciparum is present in
the mixed infection it should be accorded priority as
the most dangerous of the species infecting humans.
The agents used are determined by the geographical
origin of the parasite and thus its likely drug
sensitivity}resistance profile, and the route of
administration by the level of parasitaemia, severity
of illness, the presence of complications and the
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ability to swallow oral medication in the patient
concerned (WHO, 2000). Schizonticides effective
against P. falciparum are usually effective against P.
vivax, P. ovale and P. malariae. The asexual stages of
mixed infections containing any combination of P.
vivax, P. ovale or P. malariae can be treated with
chloroquine (or quinine if the combination is thought
to include chloroquine-resistant P. vivax). Mixed
infections which include P. vivax or P. ovale require
treatment directed against hypnozoites in the liver,
to effect a radical cure and prevent relapse. The only
agent currently marketed for this indication is the 8-
aminoquinoline, primaquine (Anon, 1991). The
standard dosage regimen is 7–5 mg twice daily for 14
days, but use of a higher dose (15 mg twice daily for
14 days) has been advocated following reports of
treatment failure at the standard dose (Doherty et al.
1997). It is essential to check the glucose-6-
phosphate-dehydrogenase (G6PD) status of the
patient prior to administering primaquine to avoid
causing haemolysis in G6PD-deficient individuals.
Malaria and helminths
Tshikuka et al. (1996) studied 1100 children and
mothers in Lubumbashi, Zaire to survey the re-
lationship between parasitic infections and clinical
syndromes to see whether single and}or multiple
species infections were risk factors for the clinical
syndromes concerned. They found no significant
interactions between Plasmodium, Ascaris lumbri-
coides, Trichuris and hookworm and no evidence of
synergism or antagonism between the parasites
present in relation to the resulting disease. In such a
situation, management of the parasitic infections
detected can proceed by treating the most dangerous
parasite first, though simultaneous treatment would
also be acceptable in the absence of a risk of drug
interaction. Fryauff et al. (1998) examined the effect
of chloroquine or primaquine anti-malarial prophy-
laxis given for one year for malaria prevention on the
presence of intestinal parasitic infections in a group
of Javanese men in Irian Jaya. They found no
significant change between baseline and endpoint in
the type of species found, the mean number of
species or ova per subject, the relative proportion of
infections caused by these species or the occurrence
of parasite free, single or multiple infections.
Malaria and other protozoa
Malarone2 (atovaquone}proguanil), a potent new
antimalarial, also has activity against Toxoplasma
and Pneumocystis carinii (via the atovaquone com-
ponent in each case), so administration of this agent
will have a wider antiparasitic effect than would be
the case with more traditional antimalarials (such as
quinine) which have a narrower spectrum of activity.
Most agents used for antimalarial chemoprophylaxis
(with the exception of proguanil which has some
causal prophylactic activity) act as schizonticides to
clear low grade asexual parasitaemia. Malarone2 has
both schizonticide and causal prophylactic activity
(against pre-erythrocytic stages of all four species of
human malaria parasites) but still lacks activity
against hypnozoites, a property possessed only by
primaquine and tafenoquine of the agents available
or on clinical trial at present. Thus, if a person is
challenged by multiple species of malaria parasites
which include P. vivax or P. ovale, a risk of a delayed
primary attack of malaria remains, unless prima-
quine or tafenoquine is used as a prophylactic agent.
In areas of high malaria endemicity, where there is
a large proportion of individuals semi-immune to
malaria, many people are asymptomatic but para-
sitaemic. In such a situation it can be difficult to
decide whether or not malarial parasitaemia is
contributing to the presenting clinical syndrome
(e.g. fever and cough) where a mixed infection may
be present. Keeping an open mind and looking, or
treating if appropriate, for other causes, whilst also
treating the malaria parasitaemia, presents a suitably
pragmatic approach to this problem.
An association between falciparum malaria and
Salmonella bacteraemia has been noted by some
authors (Gopinath, Keystone & Kain 1995; Ammah
et al. 1999; Graham et al. 2000) but felt to be
overestimated by others (Enwere et al. 1998). Full
discussion of the issue is outside the scope of this
review.
multiple parasitic infections in aids
The appearance of the Acquired Immune Deficiency
Syndrome (AIDS) had a dramatic effect on para-
sitology. The previously obscure microsporidia were
implicated in the causation of refractory diarrhoea in
late stage AIDS (Hewan-Lowe et al. 1997; Kotler &
Orenstein, 1998) and cerebral toxoplasmosis, iso-
sporiasis and cryptosporidiosis all came to promi-
nence in this condition. Pneumonia due to Pneumo-
cystis carinii (now classified amongst the fungi)
became an indicator for an AIDS diagnosis. Given
such an environment of diminished immunity it is
not surprising that a variety of parasites appeared as
co-infections and that treatment, maintenance ther-
apy or prophylaxis directed against one parasite had
an effect on other organisms present. Fortunately,
this can be turned to the patient’s advantage. Co-
trimoxazole used for prophylaxis against Pneumo-
cystis carinii also has prophylactic activity against
Toxoplasma gondii and is effective for the treatment
and maintenance therapy of Isospora belli and
Cyclospora cayetanensis. However, there may be
concerns arising from the use of cross-reactive
antiparasitic drugs. For example, atovaquone, a
second line agent for the treatment of toxoplasmosis
(Fung & Kirschenbaum, 1996; Katlama et al. 1996)
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or the prevention and treatment of pneumonia due to
Pneumocystis carinii (Castro, 1998; El-Sadr et al.
1998), has good antimalarial activity, but Plasmodium
falciparum infections readily recrudesce when
treated with atovaquone alone (Chiodini et al. 1995),
hence its use in combination with proguanil as the
product Malarone2, when it is used against malaria.
If atovaquone is deployed against Toxoplasma or
Pneumocystis in individuals exposed to frequent
malaria challenge, there is a potential to encourage
the development of atovaquone-resistant Plas-
modium falciparum.
Nowhere is the issue of unequal access to precise
laboratory diagnosis and targetted therapy more
evident than in the investigation of AIDS-associated
diarrhoea. Where the techniques are available, more
than 80% of diarrhoea cases in patients with
HIV}AIDS can be attributed to a specific entero-
pathogen and Cryptosporidium parvum, Isospora belli,
Cyclospora cayetanensis and the microsporidia ex-
plain at least 50% of cases of persistent diarrhoea
(Farthing, Kelly & Veitch 1996).
Albendazole has an unusually wide spectrum for
an antiparasitic drug, with clinically useful activity
against larval cestodes (cysticercosis, hydatid dis-
ease), Giardia, some microsporidia (Molina et al.
1998), intestinal nematodes and lymphatic filariasis.
This wide spectrum helps compliance with treatment
in a condition in which multiple drug therapy is
common. Its activity against the microsporidian
Enterocytozoon intestinalis, Giardia and intestinal
nematodes is particularly useful in the management
of AIDS-associated diarrhoea in situations in situ-
ations where precise laboratory diagnosis may not be
possible. For example, Kelly et al. (1996) examined
the effect of a 2 week, high dose (800 mg twice daily)
albendazole course versus placebo on persistent
diarrhoea of more than three weeks’ duration in 174
HIV seropositive patients in Zambia. No gastro-
intestinal investigations were performed. The
patients who received albendazole had diarrhoea on
29% fewer days than the placebo group (P!0–0001)
in the two weeks after therapy and the therapeutic
benefit of albendazole was maintained over six
months, supporting its use as empirical therapy in
the context described.
One of the most useful benefits from treating co-
infections in AIDS has come not from an anti-
parasitic drug, but from antiviral chemotherapy
directed against the underlying HIV infection. The
introduction of combination highly active anti-
retroviral therapy (HAART) has improved the
ability of patients to control AIDS-associated op-
portunistic infections. For example, Conteas et al.
(1998) looked at modification of the clinical course of
intestinal microsporidiosis due to Enterocytozoon
bieneusi in AIDS patients according to their immune
status and anti-retroviral therapy. Decreased time to
clearance of E. bieneusi was associated with per-
ipheral blood CD4 cell counts greater than or equal
to 100 mm$, the use of two or more antiretroviral
drugs, and use of a protease inhibitor.
conclusions
There is likely to be increasing recognition of the
presence and importance of multiple parasitic
infections in human hosts as more sensitive, highly
sophisticated laboratory techniques for their de-
tection become more readily available and as the
population of immunocompromised individuals in-
creases.
Broad-spectrum agents, or single delivery systems
for administration of multiple agents, will form the
mainstay of mass treatment programmes for in-
testinal parasites conducted without prior laboratory
diagnosis. Caution must always be exercised in
planning large scale antiparasitic treatment pro-
grammes, whatever the parasite or organ system
involved, to avoid the potential for adverse events
related to drug activity on concomitant infections.
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